[Skip to Navigation]
Invited Commentary
February 2016

Drilling Deeper for Treatment Choices in Diabetic Macular Edema

Author Affiliations
  • 1Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bethesda, Maryland
JAMA Ophthalmol. 2016;134(2):135-136. doi:10.1001/jamaophthalmol.2015.4652

After decades of using focal/grid laser photocoagulation to reduce the risk of vision loss with diabetic macular edema (DME), the current therapy has shifted to intravitreal injections of anti–vascular endothelial growth factor (VEGF) agents, which can result in gains in visual acuity (VA). Investigators from the Diabetic Retinopathy Clinical Research Network1 report in this issue of JAMA Ophthalmology the findings from the secondary analyses of data previously reported in a comparative trial of 3 anti-VEGF agents—aflibercept, bevacizumab, and ranibizumab—for the treatment of DME.2 The current report examines the 1-year outcomes of subgroups that were both prespecified and post hoc.1

Add or change institution